Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ADAMTS5 | Q9UNA0 | 14/20 | 0.38 |
| ▸ | MMP2 | P08253 | 5/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.38 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 2/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29289314 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2NPSR1ALDH1A1ADAMTS5MMP2 | |
| SCHEMBL13209009 | 0.82 | SMN1; SMN2 (0.42) | SMN1; SMN2NPSR1ALDH1A1ADAMTS5MMP2 | |
| SCHEMBL1404438 | 0.80 | SMN1; SMN2 (0.49) | SMN1; SMN2NPSR1ALDH1A1ADAMTS5MMP2 | |
| SCHEMBL11598874 | 0.78 | SMN1; SMN2 (0.47) | SMN1; SMN2NPSR1ALDH1A1ADAMTS5MMP2 | |
| SCHEMBL27738063 | 0.78 | SMN1; SMN2 (0.47) | SMN1; SMN2NPSR1ALDH1A1ADAMTS5MMP2 | |
| SCHEMBL6691265 | 0.77 | SMN1; SMN2 (0.46) | SMN1; SMN2NPSR1ALDH1A1ADAMTS5MMP2 | |
| SCHEMBL9190800 | 0.75 | SMN1; SMN2 (0.45) | SMN1; SMN2NPSR1ALDH1A1ADAMTS5MMP2 | |
| SCHEMBL11677504 | 0.75 | SMN1; SMN2 (0.45) | SMN1; SMN2NPSR1ALDH1A1ADAMTS5MMP2 | |
| SCHEMBL11535348 | 0.75 | SMN1; SMN2 (0.45) | SMN1; SMN2NPSR1ALDH1A1ADAMTS5MMP2 | |
| SCHEMBL11676230 | 0.75 | SMN1; SMN2 (0.45) | SMN1; SMN2NPSR1ALDH1A1ADAMTS5MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050112729-A1 | Recombinant DNA having hydantoinase gene and carbamylase gene and process for producing amino acid | AJINOMOTO CO., INC. (JP) | 2005-05-26 | — | — | US | claimed |
| CN-106380433-B | A kind of isolation and purification method of N acetyl D, L methionine | 宁夏紫光天化蛋氨酸有限责任公司 | 2018-04-20 | — | — | CN | disclosed |
| CN-106380433-A | Separation and purification method for N-acetyl-D, L-methionine | 宁夏紫光天化蛋氨酸有限责任公司 | 2017-02-08 | — | — | CN | disclosed |
| US-20060210989-A1 | Screening process for hydantoin racemases | DEGUSSA AG (DE) | 2006-09-21 | — | — | US | disclosed |
| US-20050112729-A1 | Recombinant DNA having hydantoinase gene and carbamylase gene and process for producing amino acid | AJINOMOTO CO., INC. (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1493809-A1 | RECOMBINANT DNA HAVING HYDANTOINASE GENE AND CARBAMYLASE GENE AND PROCESS FOR PRODUCING AMINO ACID | Ajinomoto Co., Inc. (JP) | 2005-01-05 | — | — | EP | disclosed |
| WO-2004111227-A2 | SCREENING PROCESS FOR HYDANTOIN RACEMASES | DEGUSSA AG (DE) | 2004-12-23 | — | — | WO | disclosed |
| EP-0219034-A2 | Process for the preparation of mesophilic microorganisms containing D-hydantoinase active at a higher temperature | BASF Aktiengesellschaft (DE) | 1987-04-22 | — | — | EP | disclosed |
| EP-0046186-B1 | METHOD OF PREPARING D-N-CARBAMOYL-ALPHA-AMINO ACIDS, AND MICROORGANISMS THEREFOR | BASF Aktiengesellschaft (DE) | 1984-05-02 | — | — | EP | disclosed |
| EP-0046186-A2 | Method of preparing D-N-carbamoyl-alpha-amino acids, and microorganisms therefor | BASF Aktiengesellschaft (DE) | 1982-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060210989-A1 | Screening process for hydantoin racemases | HARS1, AARS1, HINT1 | SMN1; SMN2 4769/4885NPSR1 681/4885ALDH1A1 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.